Page 73 - MI-2-3

Microbes & Immunity Natural phage patentability in the U.S.

AU Record AU2019205242A1 AU2014338859B2 AU2014338859B2 AU2015341683B2 AU2015341683B2 (Cont’d...)

EP Record EP3735275A1 EP3060226B1 EP3060226B1 EP3215607B1 EP3215607B1

Certain phage (s) Sa87, J-Sa36, and Sa83 BP1384, BP1429, BP1430, BP1433, BP1450, BP1644, BP1647, BP1648, BP1649, BP1650, BP1658, BP1661, and BP1662 BP1384, BP1429, BP1430, BP1433, BP1450, BP1644, BP1647, BP1648, BP1649, BP1650, BP1658, BP1661, and BP1662 BP1384, BP1777, BP1792, BP1797, BP1800, BP1902, and BP1940 BP1777, BP1792, BP1797, BP1800, BP1902, and BP1940

Sequence similarity threshold 90% (fragment) 97% (fragment) 97% (fragment) 99% (fragment) 99% (fragment)

Main claim (s) Natural phage compositions, quality, dosage, and formulation A method of using natural phage compositions (at least two phages and their dosage, and formulation) in mammals A method of using natural phage compositions (at least one phage and its dosage, and formulation) in mammals A method of using natural phage compositions (at least two phages and their dosage, and formulation) in ma

Target S. aureus P. aeruginosa P. aeruginosa P. aeruginosa P. aeruginosa

Therapeutic bacteriophage compositions for treating Phage therapy for Pseudomonas infections Phage therapy of Pseudomonas infections (continuation of U.S. Pat. (continuation of U.S. Pat.

Title infection No. 10077431) Phage therapy Phage therapy No. 10898530)

Assignee Armata Pharmaceuticals Pherecydes Pharma Pherecydes Pharma Pherecydes Pharma Pherecydes Pharma

Issue date (month/ day/year) May 23, 2023 September 18, 2018 April 16, 2019 January 26, 2021 October 10, 2023

Table 1. (Continued) US Patent number 11654166-B2 10077431-B2 10260051-B2 10898530-B2 11779617-B2

Volume 2 Issue 3 (2025) 65 doi: 10.36922/mi.4758